  | Smolen, J. S., Boers, M., Abadie, E., Breedveld, F. C., Emery, P., Bardin, T., Goel, N., Ethgen, D. J., Avouac, B. P., Dere, W. H., Durez, P., Matucci-Cerinic, M., Flamion, B., Laslop, A., Lekkerkerker, F. J., Miossec, P., Mitlak, B. H., Ormarsdottir, S., Paolozzi, L., ... Reginster, J.-Y. (2011). Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Current Medical Research and Opinion, 27 (2), 315-25. doi:10.1185/03007995.2010.542135  Peer Reviewed verified by ORBi |
  | Miossec, P., Verweij, C. L., Klareskog, L., Pitzalis, C., Barton, A., Lekkerkerker, F., Reiter, S., Laslop, A., Breedveld, F., Abadie, E., Flamion, B., Dere, W., Mpofu, S., Goel, N., Ethgen, O., Mitlak, B., Ormarsdottir, S., RAO, R. F., Tsouderos, Y., & Reginster, J.-Y. (2011). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases, 70 (10), 1713-8. doi:10.1136/ard.2011.154252 Peer Reviewed verified by ORBi |
 | Smolen, J. S., Boers, M., Abadie, E., Breedveld, F. C., Emery, P., Bardin, T., Goel, N., Ethgen, D. J., Avouac, B. P., Durez, P., Flamion, B., Laslop, A., Miossec, P., Reiter, S., & Reginster, J.-Y. (2011). Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology, 50 (10), 1732-6. doi:10.1093/rheumatology/keq413 Peer Reviewed verified by ORBi |
 | Goldhahn, J., Scheele, W. H., Mitlak, B. H., Abadie, E., Aspenberg, P., Augat, P., Brandi, M.-L., Burlet, N., Chines, A., Delmas, P. D., Dupin-Roger, I., Ethgen, D., Hanson, B., Hartl, F., Kanis, J. A., Kewalramani, R., Laslop, A., Marsh, D., Ormarsdottir, S., ... Reginster, J.-Y. (2008). Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. BONE, 43 (2), 343-7. doi:10.1016/j.bone.2008.04.017 Peer Reviewed verified by ORBi |
 | Ormarsdottir, S., Reginster, J.-Y., & Abadie, E. (2008). European regulatory perspectives for innovative therapies. Osteoporosis International, 19 (6), 725-31. doi:10.1007/s00198-008-0576-4 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Abadie, E., Delmas, P., Rizzoli, R., Dere, W., der Auwera, P., Avouac, B., Brandi, M. L., Daifotis, A., Diez-Perez, A., Calvo, G., Johnell, O., Kaufman, J. M., Kreutz, G., Laslop, A., Lekkerkerker, F., Mitlak, B., Nilsson, P., Orloff, J., ... Flamion, B. (January 2006). Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporosis International, 17 (1), 1-7. doi:10.1007/s00198-005-1984-3 Peer Reviewed verified by ORBi |
 | Altman, R. D., Abadie, E., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Menkes, C., Pavelka, K., Van De Putte, L., Vanhaelst, L., & Reginster, J.-Y. (March 2005). OC31.. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoporosis International, 16 (Suppl.3), 10. Peer Reviewed verified by ORBi |
 | Abadie, E., Devogealer, J.-P., Ringe, J., Ethgen, D., Bouvenot, G., Kreutz, G., Laslop, A., Orloff, J., Vanderauwera, P., Delmas, P., Dere, W. H., Branco, J., Altman, R. D., Avouac, B., Menkes, C. J., Vanhaelst, L., Mitlak, B., Tsouderos, Y., & Reginster, J.-Y. (March 2005). Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from GREES. Osteoporosis International, 16 (Suppl.3), 47. Peer Reviewed verified by ORBi |
 | Altman, R. D., Abadie, E., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J. P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Menkes, C. J., Pavelka, K., Van De Putte, L., Vanhaelst, L., & Reginster, J.-Y. (January 2005). Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis and Cartilage, 13 (1), 13-19. doi:10.1016/j.joca.2004.10.012 Peer Reviewed verified by ORBi |
 | Abadie, E., Devogelaer, J.-P., Ringe, J. D., Ethgen, D. J., Bouvenot, G. M., Kreutz, G., Laslop, A., Orloff, J. J., Vanderauwera, P. M., Delmas, P. D., Dere, W. H., Branco, J., Altman, R. D., Avouac, B. P., Menkes, C. J., Vanhaelst, L., Mitlak, B. H., Tsouderos, Y., & Reginster, J.-Y. (2005). Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Seminars in Arthritis and Rheumatism, 35 (1), 1-4. doi:10.1016/j.semarthrit.2005.03.006 Peer Reviewed verified by ORBi |
 | Abadie, E., Ethgen, D., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Nuki, G., Van de Putte, L., Vanhaelst, L., & Reginster, J.-Y. (April 2004). Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 12 (4), 263-268. doi:10.1016/j.joca.2004.01.006 Peer Reviewed verified by ORBi |
 | Abadie, E., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dieppe, P., Dreiser, R. L., Herrero-Beaumont, G., Kreutz, G., Laslop, A., Lemmel, E. M., Nuki, G., Van de Putte, L., & Reginster, J.-Y. (November 2003). Do new methods of investigation allow faster assessment of drugs efficacy in osteoarthritis? Osteoporosis International, 14 (Suppl. 7), 2. Peer Reviewed verified by ORBi |
 | Devogelaer, J. P., Dreiser, R. L., Abadie, E., Avouac, B., Bouvenot, G., Abello, J. C., Kaufman, J. M., Koes, B. W., Laslop, A., Lemmel, E., Richy, F., Rozenberg, S., Tavares, V., Valat, J. P., & Reginster, J.-Y. (2003). Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain. Clinical and Experimental Rheumatology, 21 (6, NOV-DEC), 691-694. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Calvo, G., Boers, M., Abadie, E., Avouac, B., Kahan, A., Kaufman, J. M., Laslop, A., Lekkerkerker, J. F., Nilsson, P., Van Zwieten-Boot, B., Kreutz, G., & Reginster, J.-Y. (2002). The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporosis International, 13 (1), 1-5. doi:10.1007/s198-002-8331-3 Peer Reviewed verified by ORBi |
 | Kaufman, J. M., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., Ben Sedrine, W., CALVO, G., Devogelaer, J. P., Fuchs, V., Kreutz, G., Nilsson, P., Pols, H., Ringe, J., Van Haelst, L., & REGINSTER, J.-Y. (2000). Background for studies on the treatment of male osteoporosis: state of the art. Annals of the Rheumatic Diseases, 59 (10), 765-72. doi:10.1136/ard.59.10.765 Peer Reviewed verified by ORBi |